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Abstract: We present the analysis of the evolution of tumors in a
case of hepatocellular carcinoma. This case is particularly informa-
tive about cancer growth dynamics and the underlying driving
mutations. We sampled nine different sections from three tumors
and seven more sections from the adjacent nontumor tissues.
Selected sections were subjected to exon as well as whole-genome
sequencing. Putative somatic mutations were then individually vali-
dated across all nine tumor and seven nontumor sections. Among the
mutations validated, 24 were amino acid changes; in addition, 22
large indels/copy number variants (>1 Mb) were detected. These
somatic mutations deﬁne four evolutionary lineages among tumor
cells. Separate evolution and expansion of these lineages were recent
and rapid, each apparently having only one lineage-speciﬁc protein-
coding mutation. Hence, by using a cell-population genetic deﬁni-
tion, this approach identiﬁed three coding changes (CCNG1, P62,
and an indel/fusion gene) as tumor driver mutations. These three
mutations, affecting cell cycle control and apoptosis, are functionally
distinct from mutations that accumulated earlier, many of which areJournal of Hepatology 20
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by Elsevier B.V. All rights reserved.Liver cancer is a deathly disease, ranking 3rd in mortality and 6th
in terms of worldwide incidence [1]. In the clinical setting, only
30% of liver cancer patients are eligible for potentially curative
treatments and even then, high recurrence rates impair optimal
patient outcome [2]. Hepatocellular carcinoma (HCC) accounts
for 80% of all diagnosed primary liver malignancies, and despite
signiﬁcant scientiﬁc advances in recent years, no clear oncogenic
addiction loops have been identiﬁed so far. New molecular tech-
nologies such as next generation sequencing (NGS) provide a
novel framework for unbiased oncogene driver discovery. Onco-
genic addiction loops identiﬁcation has facilitated personalized
approaches in other malignancies with remarkable success (e.g.
vemurafenib in BRAF-mutated melanoma [3]). Initial studies
using NGS point towards a relevant molecular complexity of
HCC [4,5]. The relative impact in tumor progression of different
cell populations within tumors has been underexplored in HCC,
as well as in other tumors. The study by Tao et al. [6] provides
a new perspective to dissect molecular heterogeneity, and to elu-
cidate major drivers during HCC progression.
Tao et al. report an exhaustive mutation analysis of three HCC
nodules from a single patient. Samples sequenced included tissue
from an initially resected tumor (T1), and two additional nodules
(T2 and T3), treated also with surgical resection. Whole genome
and exon sequencing enabled the authors to identify more than
200 common mutations and 10 distinct alterations across the
three tumors (Fig. 1). Interestingly, applying concepts derived
from the population genetics ﬁeld [7], authors were able to accu-
rately discriminate two distinct cell populations in T1. The pre-
dominant cell population in T1 contained four distinct
mutations (namely m2–m5, a deletion in 5q arm being among
them) when compared to the minor population. Eventually, these
alterations conferred a more aggressive phenotype, and favored
its outgrowth from the early population. The smallest subpopula-
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Fig. 1. Schematic representation of tumor progression pattern according to mutation proﬁle. All tumor samples harbor the background mutation proﬁle (Bkg) and
acquire additional changes (m1–m7) that discriminate each tumor. First, T2 arises from T1 after undergoing CCNG1 mutation (m1). Second, T1 cells incorporate four
mutations (m2–m5, deletion of 5q arm being among them) and this new population (blue) outgrows the early one (red). Finally, T3 arises from the predominant population
from T1 after incorporating 2 further mutations (m6 and m7, one involving P62). Genotype for each lesion is framed in black.
JOURNAL OF HEPATOLOGYsuggested to be the ﬁrst clone to arise. T2 mutation proﬁle indi-
cated it derived from this early subpopulation incorporating one
additional mutation in CCNG1 (m1) before expanding. Finally, T3
arose from the larger population since it shared m2–m5 muta-
tions and incorporated two additional ones (namely m6 and
m7, one affecting P62 gene) (Fig. 1). Authors conclude that coding
non-synonymous alterations that differentiated each nodule are
likely driving alterations and therefore, adaptive mutations. In
other words, CCNG1 (m1), a gene related to cell cycle progression
and mutated in renal cell carcinoma, would be responsible for T2
progression from the minor population in T1. A deletion in 5q
arm (m2), harboring the APC gene, would have triggered the
expansion of the predominant population in T1. P62 (m6),
involved in autophagy and apoptosis, would have contributed
to T3 growth.
NGS technology is the most recent step on the path of high-
throughput molecular analysis. Tao et al.’s study, despite not
being the ﬁrst in HCC, provides a novel approach to oncogenic
driver discovery. Through detailed analysis of a single HCC case
using population-based genetic methodology, it uncovers a struc-
tured landscape of accumulated genetic changes during HCC
evolution.
This study is the ﬁrst thorough initiative to assess clonal het-
erogeneity in HCC. Few studies have addressed this issue, and
none have used deep-sequencing data. Remarkably, they use
two platforms for whole genome sequencing and analyze up to
seven different samples from a single nodule (T1). It is also worth
highlighting the alternative approach followed by Tao et al. for
oncogenic driver discovery. The current paradigm relies on the
analysis of large cohorts of samples, mostly aimed at identifying
recurrent events. In Tao’s approach, efforts concentrate to
unleash molecular changes that deﬁne critical steps during tumor
progression in a given individual, such as cell dissemination (i.e.,
intrahepatic metastasis) or clonal outgrowth, following cell-pop-
ulation genetics principles. These changes not only discriminate
different cell populations in the cancer ecosystem, but they also
provide a molecular road map for tumor evolution. For example,
considering the two subpopulations identiﬁed in T1, the one with
less alterations is outgrown by a second population that sharesJournal of Hepatology 2012more than 98% of genetic alterations, but has four additional
mutations. These would account for its biological ﬁtness and
aggressive phenotype. From a translational standpoint, these
molecular features are the ideal candidates for selective targets
since their blockage could impact key features during HCC
progression.
However, some points decrease the relevance of the study.
Restriction to a unique individual, lacking external validation,
are clear limitations to interpret the ﬁndings, but do not affect
the originality of the approach. The key point is how we deﬁne
drivers among the identiﬁed genes. The fact that some genes
are mutated in metastatic populations compared with their pri-
mary counterparts not always deﬁne the key targets for molecu-
lar therapies. It can be that the main drivers still remain among
the 200 background mutated genes. Thus, validation in large
cohorts of patients is needed along with functional testing. Sim-
ilarly, the emerging importance on transcript from non-coding
regions in oncogenesis, such as miRNAs and epigenetic changes,
cannot be neglected since can be pivotal for tumor progression
[8]. In fact, this could address one of the concerns raised by the
authors about the relative low number of candidate driving
events found among tumors. Finally, translational relevance of
genomic studies is challenged by molecular heterogeneity. Preli-
minary data suggest that the impact of tumor heterogeneity on
transcriptomic-based classiﬁcation is mild [9], however, further
studies addressing relative relevance of tumor subpopulations
on patient outcome are needed.
In summary, the study by Tao et al. provides meaningful con-
tributions for the evaluation of HCC molecular heterogeneity
using state-of-the-art technologies. In addition, they introduce
an attractive framework for oncogenic driver discovery in HCC
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